Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
298 GBX | +1.02% | -7.74% | -15.46% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.46% | 385M | |
+7.41% | 219B | |
+5.64% | 183B | |
+10.08% | 132B | |
+23.76% | 106B | |
-2.47% | 62.09B | |
+4.81% | 50.88B | |
+11.53% | 50.8B | |
-0.65% | 40.64B | |
+24.85% | 31.59B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- Transcript : MaxCyte, Inc., 2023 Earnings Call, Mar 12, 2024